A Comprehensive Structural Overview of p38α MAPK in Complex with Type I Inhibitors
- 9 April 2015
- journal article
- review article
- Published by Wiley in ChemMedChem
- Vol. 10 (6) , 957-969
Abstract
P38α mitogen‐activated protein kinase (MAPK) is a well‐recognized therapeutic target for the treatment of autoimmune and inflammatory diseases. Over the past two decades, tremendous efforts have been focused on the discovery and development of small‐molecule p38α MAPK inhibitors, although currently no drugs targeting this protein are clinically available. Therefore, the identification of novel chemotypes that are able to inhibit p38α MAPK function is still of great therapeutic significance. With the objective to support drug discovery programs aimed at identifying new immunomodulators acting on p38α MAPK, herein we present a complete overview of the available crystal structures of this protein in complex with ATP‐site type I inhibitors. The 85 available complexes are classified by chemotype and experimental binding mode, and the ligand–protein interactions are discussed using the most representative inhibitors. The type and frequency of key inhibitor features are analyzed to give a final summary of the chemical requirements of promising p38α MAPK inhibitors. The proposed pharmacophore can be exploited to enhance the opportunities to identify novel type I inhibitors of p38α MAPK.Keywords
This publication has 85 references indexed in Scilit:
- Development of Novel In Vivo Chemical Probes to Address CNS Protein Kinase Involvement in Synaptic DysfunctionPLOS ONE, 2013
- Fluorophore Labeled Kinase Detects Ligands That Bind within the MAPK Insert of p38α KinasePLOS ONE, 2012
- Structure-based design, synthesis and biological evaluation of N-pyrazole, N′-thiazole urea inhibitors of MAP kinase p38αEuropean Journal of Medicinal Chemistry, 2012
- 1,7-Naphthyridine 1-Oxides as Novel Potent and Selective Inhibitors of p38 Mitogen Activated Protein KinaseJournal of Medicinal Chemistry, 2011
- Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell lineMolecular Cancer, 2010
- Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinibLeukemia & Lymphoma, 2009
- p38α MAP Kinase C-Terminal Domain Binding Pocket Characterized by Crystallographic and Computational AnalysesJournal of Molecular Biology, 2009
- p38MAPK: stress responses from molecular mechanisms to therapeuticsTrends in Molecular Medicine, 2009
- Are MAP Kinases Drug Targets? Yes, but Difficult OnesChemMedChem, 2007
- The Protein Data BankNucleic Acids Research, 2000